Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Efficiency of recombinant erythropoietin administration in hemoglobinopathy H.
[alpha-thalassemia]
Alpha-thalassemia
is
widely
spread
in
human
population
and
one
of
the
most
common
types
of
α-thalassemia
is
hemoglobinopathy
H
which
develops
with
mild
microcytic
hypochromic
anemia
,
hepatosplenomegaly
and
jaundice
.
The
basic
method
of
anemia
correction
is
blood
transfusion
.
However
this
method
has
crucial
deficiencies
.
As
it
is
known
recombinant
erythropoetin
(
rEPO
)
contributes
to
erythroid
proliferation
and
could
be
used
for
anemia
treatment
.
The
aim
of
the
study
was
to
qualify
efficiency
of
administration
rEPO
in
complex
therapy
of
hemaglobinopathy
H
.
Study
involved
irregularly
transfused
14
patients
with
hemoglobinopathy
H
(
2
males
and
12
females
)
.
Control
group
included
30
healthy
persons
.
Recombinant
erythropoietin
(
Eprex
)
administrated
hypodermically
10
,
000
units
3
times
a
week
during
6
months
.
Average
hemoglobin
level
before
treatment
was
62
g
/
l
.
Responses
to
the
rEPO
treatment
varied
from
9
to
70
g
/
l
,
9
(
64
%
)
of
patients
had
a
good
response
,
showed
an
increase
in
hemoglobin
level
more
than
20
g
/
l
.
In
4
patients
(
29
%
)
had
a
moderate
response
(
10
-
20
g
/
l
)
,
but
only
in
1
(
7
%
)
patient
occurred
poor
response
.
Changing
the
parameters
of
erithrocyte
indices
,
hemoglobin
fractions
,
serum
iron
and
serum
ferritin
level
are
not
statistically
significant
.
It
can
be
concluded
that
the
use
of
rEPO
in
complex
therapy
of
hemaglobinopathy
H
,
leads
to
increased
levels
of
hemoglobin
and
consequently
reducing
the
need
for
blood
transfusions
.
Diseases
Validation
Diseases presenting
"poor response"
symptom
alpha-thalassemia
carcinoma of the gallbladder
congenital adrenal hyperplasia
cushing syndrome
esophageal adenocarcinoma
hodgkin lymphoma, classical
inclusion body myositis
werner syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom